FDA panel to review risk reclassification of electroshock systems

01/24/2011 | New York Times (tiered subscription model), The

An FDA panel will hold a meeting beginning Thursday to discuss whether to reclassify electroshock devices, which are used to treat major depression, from the high-risk category to medium-risk. The FDA review comes amid calls from specialists and psychiatric groups, including the American Psychiatric Association, for the downgraded device designation.

View Full Article in:

New York Times (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX